New Jersey critical care devices maker Ikaria Inc. is rumored to be looking for an exit, hoping to claim at least $2 billion, according to unnamed sources.
Ikaria is owned by private equity and venture capital companies including Mountain Capital LLC, ARCH Venture Partners LP and Venrock Associates LP.
Hampton, N.J.-based healthcare company Ikaria won FDA clearances for an upgraded software package and 3 non-invasive respiratory care devices for use with its Inomax DSIR drug delivery system.
The Inomax DS and DSIR deliver the company’s proprietary Inomax vasodilator solution, which the company calls the only FDA-approved drug for treatment of infant hypoxic respiratory failure, associated with pulmonary hypertension.
